Description: PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Home Page: www.paxmedica.com
PXMD Technical Analysis
303 South Broadway
Tarrytown,
NY
10591
United States
Phone:
914-987-2876
Officers
| Name | Title |
|---|---|
| Mr. Michael L. Derby M.B.A., M.S. | Exec. Chairman |
| Mr. Howard J. Weisman | CEO & Director |
| Mr. Stephen Douglas Sheldon | Chief Financial Officer |
| Mr. Zachary Rome | COO & Director |
| Dr. Stefan K. F. Schwabe M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 15.2107 |
| Price-to-Book MRQ: | 10.4824 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |